Form 4: Twist Bioscience CEO Sells Shares to Cover Tax Obligations
SEC Form 4
Twist Bioscience CEO Emily M. Leproust sold 546 shares of common stock to cover tax obligations related to vesting restricted stock units.
Summary
- Emily M. Leproust, CEO of Twist Bioscience, sold 546 shares of common stock on January 3, 2025, at a price of $45.5911 per share.
- This sale was not a discretionary trade but was mandated by the company to cover tax withholding obligations associated with the vesting of restricted stock units.
- Following the transaction, Leproust directly owns 672,518 shares of Twist Bioscience common stock.
- The document also details Leproust's holdings of various employee stock options with different exercise prices and vesting schedules.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing related to stock transactions. It does not indicate any positive or negative sentiment.
Industry Context
This is a routine filing related to stock transactions by company insiders, which is common in publicly traded companies. It does not indicate any specific trend in the industry.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies in the US, and this filing is consistent with those requirements.
- The sale of shares to cover tax obligations is a common practice among executives who receive equity compensation.
Stakeholder Impact
- The sale of shares by the CEO may have a minor impact on the stock price, but it is not expected to be significant as it was for tax obligations.
Key Dates
| Date | Description |
|---|---|
| 09/01/2016 | 25% of shares subject to one of the employee stock options vested. |
| 09/28/2017 | 10% of shares subject to one of the employee stock options vested. |
| 09/28/2018 | 15% of shares subject to one of the employee stock options vested. |
| 10/31/2019 | 20% of shares subject to one of the employee stock options vested. |
| 10/24/2020 | 25% of shares subject to one of the employee stock options vested. |
| 12/19/2022 | Performance stock options vested and became exercisable. |
| 01/03/2025 | Date of the reported stock sale. |
| 01/07/2025 | Date of the signature on the Form 4. |
| 09/28/2025 | Expiration date of one of the employee stock options. |
| 09/28/2027 | Expiration date of one of the employee stock options. |
| 11/18/2028 | Expiration date of one of the employee stock options. |
| 10/23/2029 | Expiration date of one of the employee stock options. |
| 08/31/2030 | Expiration date of one of the employee stock options. |
Keywords
Twist Bioscience, Emily M. Leproust, stock sale, insider trading, Form 4, stock options, restricted stock units, tax withholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.